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http:WHAT THIS PAPER ADDS
This article demonstrates that the treatment of high risk patients with thoraco-abdominal aneurysms by
physician modiﬁed stent grafts is feasible and provides encouraging short-term results. Physician modiﬁed stent
grafts may represent a valid alternative to “off the shelf” devices for patients unable to wait for a custom made
fenestrated or branched device.Objectives: The aim was to determine whether physician modiﬁed stent grafts (PMSGs) are safe and effective for
the treatment of high risk patients with thoraco-abdominal aortic aneurysms (TAAAs).
Design: This was a retrospective single institution study.
Material: Consecutive patients with TAAA undergoing endovascular repair using a PMSG between January 2012
and June 2014 were evaluated.
Methods: Fenestrations to preserve branch vessels were created in TX2 thoracic (Cook Medical) stent grafts. Pre-
intra- and post-operative data were recorded by means of a prospectively maintained database.
Results: Eleven high risk patients with TAAA (type I, n ¼ 4; type III, n ¼ 3; type IV, n ¼ 3; type V, n ¼ 1)
underwent fenestrated endovascular repair using PMSGs. Indications were painful aneurysm (n ¼ 5), >70 mm
rapidly enlarging aneurysm (n ¼ 4), saccular aneurysm (n ¼ 1), and visceral patch false aneurysm after open
repair of a type IV TAAA (n ¼ 1). In four asymptomatic patients, an additional fenestration was created for
temporary selective sac perfusion and occluded 2e4 weeks later. Median duration for stent graft modiﬁcations
was 2 hours (range 1e3 hours). The median number of fenestrations was three (range 2e4). One patient died
during the post-operative period from colonic ischemia, giving a 9% in hospital mortality rate. Four (36%) patients
presented with moderate to severe complications. One (9%) patient presented with a paraparesis that resolved
completely after spinal ﬂuid drainage. Among surviving patients, four required early endovascular re-intervention
for type III endoleak (n ¼ 2), type Ia endoleak (n ¼ 1), or target vessel cannulation failure (n ¼ 1). The median
follow up time was 6 months (range 3e20 months). During follow up, no other complications occurred and all
target vessels remained patent. One patient presented with a persistent type II endoleak.
Conclusion: PMSGs provided acceptable short-term results and may be a management option for the treatment
of TAAA in selected high risk patients. Durability concerns need to be assessed in additional studies with long-
term follow up.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Manufactured fenestrated and branched stent grafts have
gained widespread acceptance for the treatment of patients
with thoraco-abdominal aortic aneurysms (TAAA). However,
high device costs and long manufacturing delays (6e12
weeks) limit the overall applicability of this technique.
Therefore, patients with symptomatic or large aneurysms
are not ideal candidates for fenestrated/branched stent
grafting using custom made commercial devices. Endovas-
cular alternatives include “off the shelf” devices and parallel
Table 1. Anatomical inclusion criteria for physician modiﬁed
fenestrated stent grafts.
Anatomic criterion Parameter
Aneurysm sac >70 mm and rapidly enlarging
Saccular
Non-mycotic false aneurysm
Proximal neck Diameter: 20e40 mm
Length 20 mm
Aortic angulation 45 in the visceral segment
Aortic wall Absence of ﬂoating thrombus
Absence of aortic dissection
Iliac arteries Diameter 8e20 mm
Absence of excessive tortuositya
Absence of signiﬁcant occlusive diseasea
Target vessels Diameter 5 mm
Absence of >70% ostial stenosis
Absence of previous stenting
a As deemed by multidisciplinary evaluation.
584 F. Cochennec et al.stenting approaches such as the “sandwich” technique. “Off
the shelf” fenestrated and branched devices are being
evaluated in a few expert centers.1e4 At present, they are
not widely available and still limited by anatomical re-
quirements. Parallel techniques remain complex off label
procedures.5,6 Uncertain long-term patency of recon-
structed renal/visceral vessels remains a concern, as well as
the theoretical risk of type Ia endoleak. An alternative op-
tion is a physician modiﬁed fenestrated stent graft (PMSG).
This involves deployment of a conventional stent graft de-
vice, creating customized fenestrations and reconstraining
the device into the delivery system.7e10 Some centers have
reported good short-term results for juxta- and supra-renal
aneurysms,11,12 but there is a lack of data on their appli-
cability for TAAA. Their use raises concerns on feasibility,
poor quality control, and questionable durability.
The objective of this retrospective series was to report
the authors’ experience with PMSG for TAAA in patients
unﬁt for open repair and needing rapid treatment.MATERIALS AND METHODS
Patient population
This experience with PMSGs started in January 2012.
Consecutive patients with TAAA undergoing endovascular
repair using a PMSG between January 2012 and June 2014
in the tertiary vascular unit were included. TAAAs were
classiﬁed according to the Crawford classiﬁcation.13 Pa-
tients were considered for open, hybrid, or endovascular
repair in a multidisciplinary meeting. In the current series,
all patients were deemed unﬁt for open or hybrid repair.
Indications for a PMSG were painful aneurysms, rapidly
enlarging >70 mm aneurysms, saccular aneurysms, and
visceral patch false aneurysms after TAAA open repair.
Rapidly enlarging aneurysms were deﬁned as a >5 mm
growth within 6 months. Demographic, anatomical, intra-
operative, and post-operative data were recorded by
means of a prospectively maintained database. All patients
underwent computerized tomography (CT) scan pre-
operatively and before discharge. The follow up protocol
included CT scan at 3, 6, and 12 months and yearly there-
after. Informed consent was obtained from all patients and
this study was approved by the local ethics committee
(Commission Nationale de l’informatique et des libertés).
When patients were consenting, potential risks, and ben-
eﬁts of PMSGs and manufactured stent grafts were dis-
cussed in detail and without bias. The increased risk of
infection associated with PMSGs, the lack of standardiza-
tion, and the lack of mid- and long-term data were clearly
explained.Planning and sizing
Procedure planning and device sizing were performed using
a dedicated three dimensional vascular imaging workstation
(Aquarius WS; Terarecon Inc, Mateo, CA, USA) with
centerline luminal reconstructions. Anatomic inclusion
criteria are presented in Table 1.Fenestrations were created in standard tubular or
tapered Zenith TX2 proximal thoracic components (ZTEG,
Cook Medical Inc, Bloomington, IN, USA). In some cases,
custom made Zenith TX2 devices (CMD-ZTEG, Cook) were
used, which can be ordered with custom made lengths,
diameters, and shapes and delivered within 5 days. In
contrast to standard TX2 devices, these can be provided
without proximal barbs, which facilitates reloading into the
existing delivery system.
The TX2 stent graft length was chosen to enable a
proximal landing zone of at least 25 mm in healthy aorta
and to ensure that planned fenestrations would not be on
stent overlap zones. In cases where additional proximal
thoracic components or bifurcated distal components were
necessary, the length of the stent graft components and the
position of fenestrations were calculated to ensure at least
two stent overlap. Stent graft diameters in proximal and
distal sealing zones were oversized by 15e20%.
To calculate the position of fenestrations, the superior
mesenteric artery (SMA) ostium was considered the pri-
mary reference point. Lengths to other target vessel ostia
and distance to the proximal edge of the modiﬁed TX2
device were determined on centerline reconstructions.
Relative clock positions of target vessels were determined
on coronal views, with the SMA ostium at 12 o’clock. For
calculation of arc lengths, the circumference of the modiﬁed
thoracic stent graft was divided into 48 units, each unit
representing a quarter of an hour. For each target vessel,
the theoretical arc length (TAL) from 12 o’clock (center of
SMA ostium) was calculated according to the following
formula:
TAL ¼ N  D p=48;
with N representing the number of units and D the diam-
eter of the TX2 modiﬁed stent graft.
Posterior reducing ties were used to facilitate longitudi-
nal and rotational movements of the PMSG, allowing
adjustment of the position of fenestrations to facilitate
cannulation of target vessels. Thus, the TAL was adjusted to
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posterior reducing ties reduced the graft diameter by 20e
30%14 and essentially affected the position of lateral renal
fenestrations, each renal TAL was reduced by 10e15%.
Thus, a compromise between the positions of renal fenes-
trations before and after the release of diameter reducing
ties was obtained. Modiﬁed devices included up to four
fenestrations dedicated to renal and visceral vessels. Scal-
lops were not used. Although the concept has not been
deﬁnitely proven to signiﬁcantly reduce the risk of spinal
cord ischemia, an additional fenestration was created in the
proximal thoracic component to ensure temporary sac
perfusion in some patients with asymptomatic extended
TAAAs (types I, II, or III). This fenestration was occluded
under local anesthesia 2e4 weeks after stent graft
deployment.
In one patient with >40 angulation of the visceral aorta,
two fenestrations were created for the SMA and celiac
trunk, and both renal arteries were revascularized using a
snorkel technique.Device preparation
Procedures were performed either in an endovascular suite
equipped with a Philips FD20 ﬁxed X-ray system or in an
operating room equipped with a Philips Veradius C-arm.
Stent graft modiﬁcations were performed on a back table.
They were commenced before starting anesthesia. The an-
esthesiologists started to prepare the patient when the
estimated time required to complete graft modiﬁcations
was 30 minutes. The Zenith TX2 Cook device (standard ZTEG
or CMD-ZTEG) was fully unsheathed. Proximal barbs of the
standard ZTEG devices were transected. The distance be-
tween the SMA and the proximal edge of the stent graft
was measured using a sterile ruler. The SMA fenestration
position was marked on the fabric using a sterile marking
pen. The other fenestrations were marked according to the
predetermined distances from the SMA and adjusted TAL. If
one fenestration was too close to a stent strut, the SMA
fenestration position was adjusted, and other fenestrations
re-marked so that all fenestrations were positioned in the
spaces between stent struts.
Posterior reducing ties were created according the tech-
nique described by Oderich.15 Brieﬂy, one of the three
proximal trigger nitinol wires was retrieved from the grey
inner cannula and rerouted posteriorly using a needle, along
the posterior border of the stent graft, through and through
the fabric. Z-stents were constrained using two loops of 4-
0 Prolene. A total of six to eight stent struts were
constrained.
The ﬁnal shapes of planned fenestrations were then
marked on the fabric. Their diameter corresponded to the
diameter of the covered stents selected for each target
vessel. Where sac perfusion fenestrations were deemed
necessary, these were created posteriorly next to the
proximal segment of the aortic aneurysm and away from
stent overlap zones. Fenestrations were created using a low
temperature ophthalmology cautery (OASIS Medical,Glendora, CA, USA). They were reinforced using the radio-
opaque distal tip of a 0.01400 Asahi Miraclebros guidewire
(Abbott Vascular, Abbott Park, IL, USA) or the loop of a
snare (AmplatzGooseNeck, Covidien, MN, Minneapolis,
USA), ﬁxed on the fabric with four stitches of 5-0 Prolene
and a running locking suture of CV-5 (Gore, Flagstaff, AZ,
USA). The endograft was ﬁnally reloaded in the existing
sheath using temporary 2/0 Vicryl loops to collapse each Z-
stent. In cases where a bifurcated distal component was
necessary, the proximal bare stent was removed in order to
avoid any conﬂict with bridging stents dedicated to renal
arteries.Modiﬁed stent graft implantation
Under general anesthesia, both common femoral arteries
were exposed using a standard cut down technique. Pa-
tients received 100 units/kg of heparin. One femoral access
vessel was used to deliver the modiﬁed stent graft and the
contralateral femoral was used for target vessel cannula-
tion. The procedure followed the usual steps for a Cook
fenestrated stent grafting procedure, as described previ-
ously.16 Once target vessel access was secured with Flexor
sheaths (Cook), trigger wires for the PMSG were removed
to release the posterior reducing ties. For target artery
stenting, V12 Advanta (Maquet) stents were used. Each
stent was ﬂared using Mustang 10 or 12 mm  2 cm bal-
loons (Boston Scientiﬁc). Selective control angiograms were
performed after insertion of Flexor sheaths in target vessels
and after covered stent deployment.
In cases where a thoracic fenestration was created to
maintain temporary sac perfusion, patients underwent
endovascular re-intervention under local anesthesia 2e4
weeks after stent grafting. An occlusion balloon was inﬂated
in the fenestration via a femoral puncture. After 30 minutes
of balloon occlusion with no neurologic deﬁcit, the fenes-
tration was occluded. For fenestration occlusion, an
Amplatzer device (St Jude) was deployed either directly
through the fenestration or in a V12 Advanta (Maquet)
stent inﬂated through the fenestration.RESULTS
Study population
During the study period, a total of 51 TAAA patients un-
derwent endovascular (n ¼ 24), open (n ¼ 22), or hybrid
repair (n ¼ 5). In the endovascular group, seven patients
were treated using manufactured devices with branches
and fenestrations, six patients were treated with manufac-
tured branched grafts. PMSGs were used in 11 of 24 (46%)
cases. Clinical and anatomical data of patients who under-
went endovascular repair using PMSGs are summarized in
Table 2. Indications for implantation of a PMSG were
painful/tender aneurysm (n ¼ 5), >70 mm and rapidly
enlarging aneurysm (n ¼ 4), and saccular aneurysm (n ¼ 1).
The remaining patient had a 65 mm false aneurysm arising
from a visceral patch performed 5 years earlier as part of an
open repair procedure for a type IV TAAA. As pre-operative
Table 2. Clinical and anatomic data of patients who underwent a
physician modiﬁed fenestrated stent graft.
Clinical data
Median age, yrs (range) 73 (45e89)
Males, n (%) 9 (82)
Diabetes mellitus, n (%) 1 (10)
Tobacco use in last 10 years, n (%) 9 (91)
Hypertension, n (%) 9 (91)
Hyperlipidemia, n (%) 4 (36)
Coronary artery disease, n (%) 3 (27)
Myocardial infarction, n (%) 2 (18)
Congestive heart failure, n (%) 3 (27)
Arrhythmia, n (%) 1 (9)
Cerebrovascular disease, n (%) 1 (9)
Chronic renal insufﬁciency, n (%) 2 (18)
Chronic obstructive pulmonary disease, n (%) 6 (55)
Peripheral vascular disease, n (%) 4 (36)
Cancer, n (%) 2 (18)
Obesity, n (%) 1 (9)
ASA class
ASA 3, n (%) 8 (73)
ASA 4, n (%) 3 (27)
Anatomic data
Maximal diameter in mm (mean  SD) 73  21
Type of aneurysm, n (%) Type I: 4 (36)
Type III: 3 (27)
Type IV: 3 (27)
Type V: 1 (9)
586 F. Cochennec et al.work up showed no sign of aortic infection, endovascular
treatment using a PMSG was preferred. The median number
of fenestrations was three (range 2e4). In ﬁve patients, four
fenestrations (celiac trunk, SMA, and both renal arteries)
were created. Six patients required fewer than four fenes-
trations due to pre-operative occlusion of visceral/renal
arteries (n ¼ 2), prior coil embolization of stenosed renal
arteries with atrophic kidneys (n ¼ 2), and common celiac/
superior mesenteric origin (n ¼ 1). In another patient with
>40 angulation of the visceral aorta, both renal arteries
were revascularized using a snorkel technique (Fig. 1). The
median duration for stent graft modiﬁcations was 2 hours
(range 1e3 hours).
Details of stent graft conﬁguration and intra- and post-
operative events are summarized in Table 3.Complications and re-interventions
One ASA IV patient with a type III TAAA on chronic renal
dialysis (Patient 4) died at day 31, giving a 9% in hospital
mortality rate in this series. This patient presented with an
acutely ischemic left leg on day 1, related to the occlusion
of external iliac and common femoral arteries caused by a
residual stenosis at the left common femoral access site.
The patient underwent a left external iliac thrombectomy
and a prosthetic iliofemoral bypass. Two days later, the
patient underwent a left colectomy for colic ischemia. The
etiology remained unclear. On a CT scan performed a fewhours before the colectomy, hypogastric arteries, and
bridging stents for the celiac trunk and SMA were fully
patent. Pathological examination of the left colon showed
multiple submucosal micro-thrombi. At day 15, the patient
presented with a left groin infection requiring replacement
of the prosthetic iliofemoral bypass using a contralateral
saphenous vein. This bypass occluded 2 days later and a left
transfemoral amputation was performed. The patient ﬁnally
died from multi-organ system failure.
Four (36%) patients developed moderate to severe
complications. None was directly related to stent graft
modiﬁcations. One (9%) patient (patient 2) with a type I
TAAA presented with paraparesis, with complete resolution
after spinal ﬂuid drainage. For this patient, temporary se-
lective sac perfusion was not used and aortic stent grafting
was performed as a single stage procedure. One patient
developed pneumonia and another had acute prostatitis,
resulting in a prolonged hospital stay. One patient (Patient
10) with a large type V TAAA treated using a four fenes-
tration stent graft with an additional fenestration for tem-
porary sac perfusion presented with a retroperitoneal
hematoma secondary to anastomotic bleeding at the site of
a right iliac conduit. In this patient, bilateral iliac conduits
were deemed necessary because of calciﬁed <7 mm
external iliac access vessels. The anastomotic bleeding was
treated successfully on day 1 by covered stent deployment
under local anesthesia. One month after, the temporary
fenestration was occluded but a post-operative CT scan
showed a persistent proximal type I endoleak with a 6 mm
aneurysmal sac enlargement. The patient underwent
deployment of a proximal stent component via an axillary
approach. On the last follow up CT scan, the type I endoleak
had resolved but a type II endoleak persisted, with the
aneurysm diameter remaining stable.
Three other patients required unexpected early endo-
vascular re-interventions, giving a 45% (5 of 11) early re-
intervention rate. One patient (patient 3) presented with
a type III endoleak related to suboptimal ﬂaring of the
bridging stent to the right renal artery. The covered stent
had been placed too far in the target vessel. The patient
was successfully treated by additional renal covered stent
deployment under local anesthesia (Fig. 2). Another patient
(patient 5) who underwent a four fenestration stent graft
required early endovascular re-intervention to treat a type
III endoleak. A 10 mm bridging stent had been deployed in a
12 mm celiac trunk. Despite the use of a 12 mm balloon
angioplasty to ﬂare the covered stent, sealing in the celiac
trunk was inadequate and the aneurysm still perfused.
Under local anesthesia, an additional 12 mm covered stent
was deployed more deeply in the celiac trunk. A CT scan
performed after this re-intervention showed no residual
endoleak. In the remaining patient (patient 7), the celiac
trunk could not be cannulated via a femoral approach.
Deployment of a celiac trunk bridging stent was achieved
via a brachial approach during a secondary procedure.
With the exception of the patient who presented with a
persistent type II endoleak (patient 10), aneurysm exclusion
at discharge was achieved in all surviving patients.
Figure 1. The Zenith TX2 Cook device (standard ZTEG or CMD-ZTEG) was fully unsheathed. Proximal barbs of standard ZTEG devices were
transected (A). The superior mesenteric artery fenestration position was marked on the fabric using a sterile marking pen. Using a sterile
ruler, the other fenestrations were marked (B). To create posterior reducing ties, one of the three proximal trigger nitinol wires was
retrieved from the grey inner cannula and re-routed posteriorly using a needle, along the posterior border of the stent graft, through and
through the fabric (CeE). A total of six to eight stent struts were constrained using two loops of 4-0 Prolene (F). The ﬁnal shapes of planned
fenestrations were then marked on the fabric. Fenestrations were created using a low temperature ophthalmology cautery (OASIS Medical,
Glendora, CA, USA) (G). They were reinforced using the radio opaque distal tip of a 0.01400 Asahi Miraclebros guidewire (Abbott Vascular,
Abbott Park, Ill, USA) or the loop of a snare (AmplatzGooseNeck, Covidien, USA), ﬁxed to the fabric with four stitches of 5-0 Prolene (H) and
a running locking suture of CV-5 (Gore, Flagstaff, AZ, USA) (I). The stent graft was ﬁnally reloaded in the existing sheath using temporary 2/
0 Vicryl loops to collapse each Z-stent (J). In cases where a bifurcated distal component was necessary, the proximal bare stent was
removed (K).
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months (range 3e20 months). Two patients were lost to
follow up after 3 months. Two patients were followed up
beyond 1 year. No additional complications or endoleaks
occurred during the follow up period. Target vessels and
bridging stents remained patent. Aneurysm diameters
remained stable.DISCUSSION
With a 9% in hospital mortality rate and a 9% spinal cord
ischemia rate, PMSG for TAAA provided acceptable short-
term results for this high risk patient population. All sur-
viving patients were alive and well with only one patient
presenting with a persistent type II endoleak at the end of
the follow up period. Cumulative data from previous
Table 3. Stent graft conﬁguration, intra- and post-operative events.
Patients Type of TAAA, anatomic details Anatomic characteristics making
patients unsuitable for an off
the shelf t-branch device
Stent graft conﬁguration Intra-operative
complications
Post-operative complications/
re-interventions
1 Symptomatic (tender) 45 mm saccular
type IV, SMA and CA occluded
pre-operatively, IMA and left colonic
arcade well developed
Two target vessels (SMA and CA
occluded pre-operatively)
Modiﬁed ZTEG with two fn (RRA,
LRA) deployed above the IMA
None None
2 Asymptomatic 71 mm type I TAAA Aortic diameter <25 mm at the
level of renal arteries
Proximal ZTEG þ modiﬁed ZTEG
with 4 fn (CA, SMA, RRA, LRA)
None Incomplete paraplegia,
regressive after SFD
Iatrogenic meningitis
3 Asymptomatic 75 mm type I TAAA,
previous aortic arch repair (frozen
elephant trunk technique), CA occluded
Three target vessels (CA occluded)
Target vessels not accessible from
antegrade approach due to recent
frozen elephant trunk technique
Modiﬁed proximal CMD-ZTEG (1 fn
for temporary sac perfusion) þ
modiﬁed ZTEG with 3 fn (SMA,
RRA, LRA)
None Endovascular re-intervention
for type III EL: deployment
of an additional covered
stent in the RRA
4 Symptomatic (tender) 65 mm type
III TAAA
Two target vessels (bilateral renal
embolization)
Renal embolization þ modiﬁed
ZTEG with 2 fn (SMA, CA)þ Zenith
AAA bifurcated stent graft.
None Lower limb ischemia, colic
ischemia, death
5 Asymptomatic 65 mm false aneurysm
of the visceral patch after OR for a
type IV TAAA
None Modiﬁed CMD-ZTEG with 4 fn
(CA, SMA, RRA, LRA) þ Zenith
bifurcated stent graft
None Endovascular re-intervention
for type III EL: deployment
of an additional covered
stent in the CA
6 Symptomatic (tender) 130 mm type
I TAAA; 45 mm aneurysm of the distal
arch (left untreated)
Aortic diameter <25 mm at the
level of renal arteries
Proximal ZTEG þ modiﬁed ZTEG
with 2 fn (CA, SMA)þ snorkel
for RRA and LRA þ distal ZTEG
None None
7 Asymptomatic 75 mm type III TAAA,
stenotic RRA with atrophic kidney
Target vessels not accessible from
antegrade approach (gothic arch)
RRA embolization, modiﬁed proximal
ZTEG (1 fn for temporary sac
perfusion) þ modiﬁed ZTEG with 3
fn (CA, SMA, LRA) þ Zenith bifurcated
stent graft
CA cannulation
failure
Pneumonia, endovascular
re-intervention for CA
cannulation and bridging
stent deployment
8 Asymptomatic 55 mm sacciform type
IV TAAA
Three target vessels (common
celiac/superior mesenteric origin)
Modiﬁed CMD-ZTEG with 3 fn
(common celiac/superior mesenteric
origin, RRA, LRA)
None None
9 Asymptomatic 70 mm type I TAAA Upward orientation of the left
renal artery
Modiﬁed proximal ZTEG (1 fn for
temporary sac perfusion) þ modiﬁed
ZTEG with 4 fn (CA, SMA, RRA, LRA)
None Acute prostatitis
10 Asymptomatic 82 mm Type V TAAA,
HIV encephalitis. CA occluded
CA occluded Bilateral iliac conduits, modiﬁed
CMD-ZTEG with 1 fn for temporary
sac perfusion and 4 fn for CA, SMA,
RRA, LRA, accessory LRA.
None Re-interventions for
retroperitoneal hemorrhage
and type I endoleak.
Persistent type II endoleak
11 Symptomatic (tender) 75 mm type
III TAAA. 50 mm aneurysm of the
distal arch (left untreated)
Aortic diameter <25 mm at the
level of visceral arteries
Modiﬁed ZTEG with 4 fn (CA, SMA,
RRA, LRA) þ Zenith bifurcated
stent graft
None None
CA ¼ celiac artery; CMD ¼ custom made; EL ¼ endoleak; fn ¼ fenestration; IMA ¼ inferior mesenteric artery; LRA ¼ left renal artery; OR ¼ open repair; RRA ¼ right renal artery;
SFD ¼ spinal ﬂuid drainage; SMA ¼ superior mesenteric artery; TAAA ¼ thoraco-abdominal aortic aneurysm; TX2 ¼ TX2 (Cook) thoracic stent graft; ZTEG ¼ Zenith TX2 proximal
component (Cook).
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Figure 2. Patient with a recent history of aortic arch aneurysm treated by a frozen elephant trunk technique using an open-Evita device (A).
A post-operative computed tomography scan showed a 75 mm rapidly enlarging type I thoraco-abdominal aortic aneurysm (B). The celiac
trunk was occluded. The patient was treated using a physician modiﬁed fenestrated stent graft with three fenestrations for the renal and
superior mesenteric arteries. An additional temporary fenestration was created for temporary sac perfusion and occluded 3 weeks later
using an Amplatzer Occluder (St. Jude) device (black arrow, C). A post-operative computed tomography showed a persistent type III
endoleak (C,D) that resolved after placement of an additional right renal covered stent (E,F).
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deserves consideration in a selected group of high risk pa-
tients for whom aneurysm repair cannot be delayed.
The available options to treat high risk patients with
TAAA in acute or subacute settings are limited. Even in high
volume centers, open repair is associated with mortality
rates of 5e15% and spinal cord ischemia rates of 3e
15%.17e21 In emergency cases, these mortality rates in-
crease to 20e40%.20,22 Hybrid procedures combining
debranching of visceral arteries and aortic stent grafting
have the theoretical advantage of avoiding aortic cross
clamping and extracorporeal circulation. However, there is
no evidence that hybrid procedures are superior to con-
ventional open repair in terms of post-operative mortality
and paraplegia. A recent meta-analysis including 507 pa-
tients from 19 publications showed that hybrid procedures
were still associated with signiﬁcant in hospital mortality
(12.8%) and spinal cord ischemia rates (7.5%).23 Parallel
techniques such as the sandwich technique constitute
purely endovascular alternatives. Encouraging short-term
results have been reported in small series5,6 but type Ia
endoleaks through the gutters and uncertainty regarding
the long-term patency of visceral artery covered stents re-
mains a concern. Standardization in such procedures is also
lacking. During the last 10 years, fenestrated/branchedstent grafts have played a growing role in the management
of TAAA. Expert centers have reported low peri-operative
morbidity and mortality rates and excellent mid-term re-
sults.24e27 However, commercial custom made devices
require at least 6e12 weeks to be manufactured, thereby
precluding the treatment of patients requiring urgent
intervention, or expedited treatment. Recently, off the shelf
multi-branched devices have been introduced in order to
offer an endovascular alternative to emergent patients.1e
4,28 These devices are still under evaluation and not
widely available. In France, only one device (t-branch de-
vice, Cook) is ﬁnanced by the Social Security system and the
indications are limited to type IV TAAAs. However, off the
shelf devices are likely to play a growing role in the man-
agement of TAAAs and may reduce the potential indications
for PMSG. Preliminary series have provided good short-term
results. Bisdas et al.2 recently reported their experience
with custom made and off the shelf (t-branch) multi-
branched Cook devices. The t-branch device showed 100%
technical success and similar clinical outcomes to the
custom made device. The current design is theoretically
applicable in 50e90% of anatomical conﬁgurations.28,29
Therefore, some patients will still require custom made
stent grafts. In their study, Bisdas et al.2 also identiﬁed the
main obstacles that would make the t-branch unsuitable for
590 F. Cochennec et al.implantation: distance between the celiac trunk and the
most caudal renal artery >56 mm, insufﬁcient luminal
diameter (<25 mm) at the level of the visceral arteries,
upward orientation of at least one renal artery, and a dis-
tance 67 mm between the most caudal renal artery and the
aortic bifurcation.2 Bisdas et al.2 also reported the avail-
ability of four target vessels accessible from an antegrade
approach as being an anatomic inclusion criterion. Accord-
ing to these anatomic criteria, only one patient of the
current series was suitable for a t-branch device (Table 3).
However, some of the other patients could have become so
with adjunctive procedures. Vascular plugs for side-branch
occlusion could have been used for patients with only
two or three patent target vessels. Using through and
through wires for antegrade cannulation could have over-
come the problem of angulated aortic arches.
PMSGs could have several theoretical advantages. In
contrast to the ﬁxed three stents of the t-branch, the
number of stents in the proximal part can be chosen when
using PMSGs. This could permit less coverage of the
thoracic aorta. Moreover, in order to permit use of t-branch
devices in a large number of patients, the ideal position for
visceral branches is usually compromised for one or more of
the target vessels. This could potentially lead to an
increased risk of target vessel cannulation failure and long-
term branch occlusion. While awaiting the arrival of reliable
and universal off the shelf stent grafts and on the basis of
previous reports from pioneering centres,9,11 PMSGs
constitute a valid option for the treatment of TAAA in
selected patients.
In this study, asymptomatic patients were candidates for
a PMSG only when the aneurysm diameter exceeded
70 mm and was rapidly enlarging. These criteria are not
evidence based as the natural history of TAAA disease is
poorly understood. However, there are data in the literature
to suggest that aortic aneurysms >70 mm should be
treated rapidly. Coady et al.30 reported a drastic increase in
the risk of rupture beyond 70 mm for aneurysms of the
descending thoracic aorta. When looking at available data
on abdominal aortic aneurysms, the annual risk of rupture
for diameters >70 mm has been estimated to be >30%.31
Therefore, 70 mm was considered to be an acceptable
threshold to offer patients the possibility of rapid treatment
using a PMSG.
In the current series, one patient died and one pre-
sented with transitory paraplegia. The single death was
related to a colonic ischemia and occurred in an ASA 4
patient with a tender aneurysm and multiple comorbid-
ities. The cause of the colonic ischemia remained unclear
but was probably multifactorial. The bridging stent dedi-
cated to the SMA remained patent. Retrospectively,
although this compassionate endovascular procedure was
technically straightforward, the patient may have lacked
the physiological reserve to recover from such a proce-
dure. Nevertheless, the results are similar to contemporary
short-term results of fenestrated/branched stent grafts for
TAAA. In expert hands, fenestrated/branched stent grafting
for TAAA using commercial devices has been associatedwith 30 day mortality rates ranging from 5% to 12% and
spinal cord ischemia rates ranging from 3% to 17%.26,32e35
The group has recently pointed out that these results
might not reﬂect “real-life” practice.36 Indeed, using
commercial custom made or off the shelf devices in 24
TAAA patients, a 12.5% 30 day mortality was reported.
Although the restricted number of patients does not allow
a reliable statistical comparison, the short-term results
using PMSGs to date have been at least comparable if not
favorable.
To date, only a few centers have reported results with the
use of PMSGs in the management of complex aortic an-
eurysms. This approach has been used predominantly for
juxtarenal aneurysms. A case series published in 2012 re-
ported outcomes in 47 high risk patients treated with
PMSGs for symptomatic or rapidly enlarging juxtarenal an-
eurysms.11 Again, results were similar to those in the cur-
rent literature on commercial custom made fenestrated
stent grafts, with 30 day mortality and complication rates of
2% and 13% respectively. Encouraged by those initial re-
sults, a further 28 patients were included in an investigator
sponsored device exemption study,37 with 30 day mortality
rates and freedom from sac enlargement at 12 months of
3.8% and 87.5% respectively. Regarding the use of PMSGs
for the treatment of TAAA, publications are scarce, con-
sisting of a few limited series or individual cases.7e10,38 To
our knowledge, the largest experience comes from the
Mayo Clinic.39 Recently, Oderich et al. presented results
comparing the use of 30 PMSGs with 16 hybrid repairs for
high risk patients with complex aortic aneurysms. Pro-
portions of TAAA patients were 47% in the PMSG group and
81% in the hybrid group. When compared with the hybrid
group, PMSGs were associated with reduced blood loss, less
ﬂuid requirements and shorter total operative time. Post-
operative mortality rates were 3.3% in the PMSG group
and 19% in the hybrid group.
Although the use of PMSGs seems to be an effective
alternative for selected patients with TAAAs, several dis-
advantages must be considered. The early re-intervention
rate was high (45%). Even if still in the learning curve, it
reﬂects the fact that this off label procedure is technically
challenging and that graft modiﬁcation lacks standardiza-
tion, varying from one center and one operator to another.
PMSGs cannot be applied in hemodynamically unstable
patients. Indeed, the median duration for stent graft
modiﬁcation was 2 hours, taking up to 3 hours in some
cases. Moreover, even if performed in sterile conditions,
deploying the stent graft on a back table for modiﬁcation
could be associated with an increased risk of infection. This
complication was not observed in the present series. Long-
term results are poorly understood and this constitutes
another restriction to PMSGs. Lastly, modifying an
implantable medical device is associated with obvious legal
risks as the physician becomes fully responsible for the
modiﬁcations. Thus, the use of PMSGs should be restricted
to patients unﬁt for open repair and at risk for rupture in
the short-term, with the support of an experienced multi-
disciplinary team.
Treatment of Thoraco-abdominal Aortic Aneurysms Using Physician Modiﬁed Fenestrated Stent Grafts 591Although the concept lacks evidence, branch grafts are
usually preferred for large TAAAs, especially when the
calculated distance between the deployed aortic device and
the origin of the target vessel is >10 mm. In such cases,
branches might reduce the risks of cannulation failure and
long term bridging stent occlusion/disconnection related to
aneurysm shrinkage. Although the feasibility of immediate
stent graft modiﬁcations using perfusion branches was re-
ported previously,15,38 perfusion of critical branch vessels
was maintained using fenestrations rather than branches.
This option was considered acceptable since, apart from
one case (patient 8, 55 mm saccular type IV TAAA), the
calculated distances between the deployed aortic device
and the origin of target vessels did not exceed 10 mm. As
regards patient 8, all target vessels remained patent at
three months.
In the present series, one patient (patient 2) with an
asymptomatic 71 mm type I TAAA presented with post-
operative partial paraplegia, completely reversed after spi-
nal ﬂuid drainage. Subsequently, additional fenestrations
were created to ensure temporary sac perfusion in patients
with asymptomatic type III, type I, or type V aneurysms
(there were no patients with type II TAAA in the present
series). Although there is no evidence this strategy can
signiﬁcantly reduce the risk of paraplegia, the four patients
treated using temporary fenestrations for selective sac
perfusion remained free from spinal cord ischemia after
closure of the fenestration.
CONCLUSION
Short-term results are promising using PMSGs for the
treatment of TAAA.
Until reliable and applicable “off the shelf” stent grafts
become widely available, PMSGs may be a valid option for
high risk patients, unable to wait for a custom made
fenestrated or branched device. However, long-term follow
up is needed before fully endorsing this novel approach in
the treatment of TAAA.
CONFLICT OF INTEREST
None.
FUNDING
None.
REFERENCES
1 Bisdas T, Donas KP, Bosiers M, Torsello G, Austermann M.
Anatomical suitability of the T-branch stent graft in patients
with thoraco-abdominal aortic aneurysms treated using
custom made multibranched endografts. J Endovasc Ther
2013;20(5):672e7.
2 Bisdas T, Donas KP, Bosiers MJ, Torsello G, Austermann M.
Custom made versus off the shelf multibranched endografts
for endovascular repair of thoraco-abdominal aortic aneu-
rysms. J Vasc Surg 2014;60(5):1186e95.
3 Bosiers MJ, Bisdas T, Donas KP, Torsello G, Austermann M. Early
experience with the ﬁrst commercially available off the shelf
multibranched endograft (t-branch) in the treatment ofthoraco-abdominal aortic aneurysms. J Endovasc Ther
2013;20(6):719e25.
4 Chuter TA, Hiramoto JS, Park KH, Reilly LM. The transition from
custom made to standardized multibranched thoraco-
abdominal aortic stent grafts. J Vasc Surg 2011;54(3):660e7
[discussion 667e8].
5 Kolvenbach RR, Yoshida R, Pinter L, Zhu Y, Lin F. Urgent
endovascular treatment of thoraco-abdominal aneurysms us-
ing a sandwich technique and chimney graftsda technical
description. Eur J Vasc Endovasc Surg 2011;41(1):54e60.
6 Lobato AC, Camacho-Lobato L. A new technique to enhance
endovascular thoraco-abdominal aortic aneurysm therapyethe
sandwich procedure. Semin Vasc Surg 2012;25(3):153e60.
7 Oderich GS, Fatima J, Gloviczki P. Stent graft modiﬁcation with
mini-cuff reinforced fenestrations for urgent repair of thoraco-
abdominal aortic aneurysms. J Vasc Surg 2011;54(5):1522e6.
8 Oderich GS, Mendes BC, Correa MP. Preloaded guidewires to
facilitate endovascular repair of thoraco-abdominal aortic
aneurysm using a physician modiﬁed branched stent graft.
J Vasc Surg 2014;59(4):1168e73.
9 Oderich GS, Ricotta 2nd JJ. Modiﬁed fenestrated stent grafts:
device design, modiﬁcations, implantation, and current appli-
cations. Perspect Vasc Surg Endovasc Ther 2009;21(3):157e67.
10 Ricotta 2nd JJ, Tsilimparis N. Surgeon-modiﬁed fenestrated-
branched stent grafts to treat emergently ruptured and
symptomatic complex aortic aneurysms in high risk patients.
J Vasc Surg 2012;56(6):1535e42.
11 Starnes BW. Physician modiﬁed endovascular grafts for the
treatment of elective, symptomatic, or ruptured juxtarenal
aortic aneurysms. J Vasc Surg 2012;56(3):601e7.
12 Starnes BW, Quiroga E. Hybrid-fenestrated aortic aneurysm
repair: a novel technique for treating patients with para-
anastomotic juxtarenal aneurysms. Ann Vasc Surg 2010;24(8):
1150e3.
13 Crawford ES, Crawford JL, Saﬁ HJ, Coselli JS, Hess KR, Brooks B,
et al. Thoraco-abdominal aortic aneurysms: pre-operative and
intra-operative factors determining immediate and long-term
results of operations in 605 patients. J Vasc Surg 1986;3(3):
389e404.
14 Oderich GS. Diameter reducing wire to facilitate deployment of
a modiﬁed Zenith fenestrated stent graft. Ann Vasc Surg
2010;24(7):980e4.
15 Oderich GS. Technique of adding a diameter reducing wire to
the modiﬁed TX2 fenestrated stent graft. Vascular 2010;18(6):
350e5.
16 Oderich GS, Correa MP, Mendes BC. Technical aspects of repair
of juxtarenal abdominal aortic aneurysms using the Zenith
fenestrated endovascular stent graft. J Vasc Surg 2014;59(5):
1456e61.
17 Acher C,Wynn M. Outcomes in open repair of the thoracic and
thoraco-abdominal aorta. J Vasc Surg 2010;52(Suppl. 4):3Se9S.
18 Cambria RP, Clouse WD, Davison JK, Dunn PF, Corey M,
Dorer D. Thoraco-abdominal aneurysm repair: results with 337
operations performed over a 15 year interval. Ann Surg
2002;236(4):471e9 [discussion 479].
19 Coselli JS, Bozinovski J, LeMaire SA. Open surgical repair of
2286 thoraco-abdominal aortic aneurysms. Ann Thorac Surg
2007;83(2):S862e4 [discussion S890e2].
20 Piazza M, Ricotta 2nd JJ. Open surgical repair of thoraco-
abdominal aortic aneurysms. Ann Vasc Surg 2012;26(4):600e5.
21 Svensson LG, Crawford ES, Hess KR, Coselli JS, SaﬁHJ. Experience
with 1509 patients undergoing thoraco-abdominal aortic oper-
ations. J Vasc Surg 1993;17(2):357e68 [discussion 368e70].
592 F. Cochennec et al.22 Rigberg DA, McGory ML, Zingmond DS, Maggard MA,
Agustin M, Lawrence PF, et al. Thirty-day mortality statistics
underestimate the risk of repair of thoraco-abdominal aortic
aneurysms: a statewide experience. J Vasc Surg 2006;43(2):
217e22 [discussion 223].
23 Moulakakis KG, Mylonas SN, Avgerinos ED, Kakisis JD,
Brunkwall J, Liapis CD. Hybrid open endovascular technique for
aortic thoraco-abdominal pathologies. Circulation
2011;124(24):2670e80.
24 Greenberg R, Eagleton M, Mastracci T. Branched endografts for
thoraco-abdominal aneurysms. J Thorac Cardiovasc Surg
2010;140(Suppl. 6):S171e8.
25 Greenberg RK, Lytle B. Endovascular repair of thoraco-
abdominal aneurysms. Circulation 2008;117(17):2288e96.
26 Haulon S, D’Elia P, O’Brien N, Sobocinski J, Perrot C, Lerussi G,
et al. Endovascular repair of thoraco-abdominal aortic aneu-
rysms. Eur J Vasc Endovasc Surg 2010;39(2):171e8.
27 Verhoeven EL, Tielliu IF, Ferreira M, Zipfel B, Adam DJ. Thoraco-
abdominal aortic aneurysm branched repair. J Cardiovasc Surg
(Torino) 2010;51(2):149e55.
28 Sweet MP, Hiramoto JS, Park KH, Reilly LM, Chuter TA.
A standardized multi-branched thoraco-abdominal stent graft
for endovascular aneurysm repair. J Endovasc Ther 2009;16(3):
359e64.
29 Azzaoui R, Sobocinski J, Maurel B, D’Elia P, Perrot C,
Bianchini A, et al. Anatomic study of juxta renal aneurysms:
Impact on fenestrated stent grafts. Ann Vasc Surg 2011;25(3):
315e21.
30 Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U,
Kopf GS, et al. What is the appropriate size criterion for
resection of thoracic aortic aneurysms? J Thorac Cardiovasc
Surg 1997;113(3):476e91 [discussion 489e91].
31 Moll FL, Powell JT, Fraedrich G, Verzini F, Haulon S,Waltham M,
et al. Management of abdominal aortic aneurysms clinicalpractice guidelines of the European society for vascular sur-
gery. Eur J Vasc Endovasc Surg 2011;41(Suppl. 1):S1e58.
32 Chuter TA, Rapp JH, Hiramoto JS, Schneider DB, Howell B,
Reilly LM. Endovascular treatment of thoraco-abdominal aortic
aneurysms. J Vasc Surg 2008;47(1):6e16.
33 Greenberg RK, Lu Q, Roselli EE, Svensson LG, Moon MC,
Hernandez AV, et al. Contemporary analysis of descending
thoracic and thoraco-abdominal aneurysm repair: a compari-
son of endovascular and open techniques. Circulation
2008;118(8):808e17.
34 Roselli EE, Greenberg RK, Pfaff K, Francis C, Svensson LG,
Lytle BW. Endovascular treatment of thoraco-abdominal aortic
aneurysms. J Thorac Cardiovasc Surg 2007;133(6):1474e82.
35 Verhoeven EL, Tielliu IF, Bos WT, Zeebregts CJ. Present and
future of branched stent grafts in thoraco-abdominal aortic
aneurysm repair: a single centre experience. Eur J Vasc Endo-
vasc Surg 2009;38(2):155e61.
36 Cochennec F, Kobeiter H, Gohel MS, Majewski M, Marzelle J,
Desgranges P, et al. Impact of intra-operative adverse events
during branched and fenestrated aortic stent grafting on post-
operative outcome. J Vasc Surg 2014;60(3):571e8.
37 Starnes BW, Tatum B. Early report from an investigator-
initiated investigational device exemption clinical trial on
physician modiﬁed endovascular grafts. J Vasc Surg 2013;58(2):
311e7.
38 Jim J, Sanchez LA, Rubin BG. Use of a surgeon-modiﬁed
branched thoracic endograft to preserve an aortorenal
bypass during treatment of an intercostal patch aneurysm.
J Vasc Surg 2010;52(3):730e3.
39 Oderich GS. Reporting on fenestrated endografts: surrogates
for outcomes and implications of aneurysm classiﬁcation, type
of repair, and the evolving technique. J Endovasc Ther
2011;18(2):154e6.
